Business · 09/09/2010Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for REPEL-CV Patent Extension
Summary
The Food and Drug Administration has officially confirmed the regulatory review period for the patent extension application of REPEL-CV, a medical device patent, as required by law, following a submission to the Director of Patents and Trademarks at the Department of Commerce.
Original source language: Federal Register — Health and Human ServicesOpen original release →